The effect of coenzyme Q10 on the pharmacokinetic parameters of theophylline

被引:8
作者
Baskaran, Rengarajan [1 ]
Shanmugam, Srinivasan [1 ]
Nagayya-Sriraman, Santhoshkumar [1 ]
Kim, Ju Hyun [1 ]
Jeong, Tae Chun [1 ]
Yong, Chul Soon [1 ]
Choi, Han-Gon [1 ]
Yoo, Bong Kyu [1 ]
机构
[1] Yeungnam Univ, Coll Pharm, Kyongsan 712749, Kyungbuk, South Korea
关键词
theophylline; coenzyme Q10; pharmacokinetic parameters; protein binding; cytochrome P450;
D O I
10.1007/s12272-001-1250-1
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Interaction of a drug with other drugs and dietary supplements is becoming an emerging issue for patients and health insurance authorities due to awareness of adverse drug event. In this study, we examined the effects of coenzyme Q10 (CoQ10), one of the most popular dietary supplements, on the pharmacokinetic parameters of theophylline in rats. The pharmacokinetic parameters of theophylline changed significantly when the drug was administered after five consecutive days of pretreatment with CoQ10. Time to reach maximum plasma concentration of theophylline delayed when the drug was administered after the pretreatment with CoQ10. Maximum plasma concentration and area under the curve of theophylline were about two-fold increased and other pharmacokinetic parameters such as half-life and volume of distribution were also changed significantly. Therefore, although CoQ10 is generally considered a safe dietary supplement, it appears that patients on theophylline therapy should use caution when they take CoQ10.
引用
收藏
页码:938 / 944
页数:7
相关论文
共 36 条
  • [1] *AHFS, 2007, AHFS DRUG INF
  • [2] EXOGENOUS COQ(10) PRESERVES PLASMA UBIQUINONE LEVELS IN PATIENTS TREATED WITH 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE INHIBITORS
    BARGOSSI, AM
    BATTINO, M
    GADDI, A
    FIORELLA, PL
    GROSSI, G
    BAROZZI, G
    DIGIULIO, R
    DESCOVICH, G
    SASSI, S
    GENOVA, ML
    LENAZ, G
    [J]. INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1994, 24 (03) : 171 - 176
  • [3] BLANK JA, 1987, MOL PHARMACOL, V32, P168
  • [4] Bonakdar RA, 2005, AM FAM PHYSICIAN, V72, P1065
  • [5] New pharmacologic horizons in the treatment of Parkinson disease
    Bonuccelli, Ubaldo
    Del Dotto, Paolo
    [J]. NEUROLOGY, 2006, 67 (07) : S30 - S38
  • [6] BRUNTON R, 2005, GOODMAN GILMANS PHAR
  • [7] Use of dietary supplements among United States adults with coronary artery disease and atherosclerotic risks
    Buettner, Catherine
    Phillips, Russell S.
    Davis, Roger B.
    Gardiner, Paula
    Mittleman, Murray A.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (05) : 661 - 666
  • [8] Conklin Kenneth A, 2005, Integr Cancer Ther, V4, P110, DOI 10.1177/1534735405276191
  • [9] Biochemical functions of coenzyme Q10
    Crane, FL
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 2001, 20 (06) : 591 - 598
  • [10] Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS
    Ferrante, KL
    Shefner, J
    Zhang, H
    Betensky, R
    O'Brien, M
    Yu, H
    Fantasia, M
    Taft, J
    Beal, MF
    Traynor, B
    Newhall, K
    Donofrio, P
    Caress, J
    Ashburn, C
    Freiberg, B
    O'Neill, C
    Paladenech, C
    Walker, T
    Pestronk, A
    Abrams, B
    Florence, J
    Renna, R
    Schierbecker, J
    Malkus, B
    Cudkowicz, M
    [J]. NEUROLOGY, 2005, 65 (11) : 1834 - 1836